Comparative sequencing study of mismatch repair and homology‐directed repair genes in endometrial cancer and breast cancer patients from Kazakhstan
Ying Zheng,Natalia Vdovichenko,Peter Schürmann,Dhanya Ramachandran,Robert Geffers,Lisa‐Marie Speith,Natalia Bogdanova,Julia Enßen,Natalia Dubrowinskaja,Tatyana Yugay,Zura Berkutovna Yessimsiitova,Nurzhan Turmanov,Peter Hillemanns,Thilo Dörk
DOI: https://doi.org/10.1002/ijc.35215
2024-10-16
International Journal of Cancer
Abstract:What's New? In high‐risk families, endometrial cancer appears to be mainly triggered by pathogenic variants in mismatch repair genes, and breast cancer by pathogenic variants in homology‐directed repair genes. However, the two pathways are not mutually exclusive. This comparative single‐center sequencing study of hereditary cancer susceptibility variants in 342 endometrial cancer patients and 178 breast cancer patients in Kazakhstan indicates that gene variants from the two pathways with predicted pathogenicity occur at substantial frequencies in both breast and endometrial cancer. The broader presence of the gene variants could provide additional therapeutic opportunities for individualized treatment regimens in endometrial and breast cancer. Endometrial cancer has been associated with pathogenic variants in mismatch repair (MMR) genes, especially in the context of the hereditary Lynch Syndrome. More recently, pathogenic variants in genes of homology‐directed repair (HDR) have also been suggested to contribute to a subset of endometrial cancers. In the present hospital‐based study, we investigated the relative distribution of pathogenic MMR or HDR gene variants in a series of 342 endometrial cancer patients from the Oncology Clinic in Almaty, Kazakhstan. In comparison, we also sequenced 178 breast cancer patients from the same population with the same gene panel. Identified variants were classified according to ClinVar, ESM1b, and AlphaMissense prediction tools. We found 10 endometrial cancer patients (2.9%) carrying pathogenic or likely pathogenic variants in MMR genes (7 MSH6, 1 MSH2, 2 MUTYH), while 14 endometrial cancer patients (4.1%) carried pathogenic variants in HDR genes (4 BRCA2, 3 BRCA1, 3 FANCM, 2 SLX4, 1 BARD1, 1 BRIP1). In the breast cancer series, we found 8 carriers (4.5%) of pathogenic or likely pathogenic variants in MMR genes (2 MSH2, 2 MSH6, 4 MUTYH) while 12 patients (6.7%) harbored pathogenic or likely pathogenic HDR gene variants (5 BRCA1, 3 BRCA2, 1 BRIP1, 1 ERRC4, 1 FANCM, 1 SLX4). One patient who developed breast cancer first and endometrial cancer later carried a novel frameshift variant in MSH6. Our results indicate that MMR and HDR gene variants with predicted pathogenicity occur at substantial frequencies in both breast and endometrial cancer patients from the Kazakh population.
oncology